1. Introduction {#sec0005}
===============

Cell membrane chromatography (CMC), a biological Chromatographic technique proposed by He' group in 1996 [@bib0005],[@bib0010], has been successfully applied to studying the interac-tions between ligands and membrane reeeptors [@bib0015], [@bib0020], [@bib0025]. The results obtained from CMC assay are consistent with those from radioligand binding assay (RLA) significantly [@bib0030],[@bib0035]. CMC has been proved to be an effective tool for screening of active components targeting membrane reeeptors from traditional Chinese medicines (TCMs) [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060]. CMC, as an approach to recognition of active components, combined with other Separation and identif ication techniques as well as pharmacological verification trials, will provide another way to rapidly discover target components from complex system [@bib0065], [@bib0070], [@bib0075]. CMC has already been applied to investi-gate the TCMs. In fact, the study of complex biological samples is also count for much. Under the environment of enzymes and body fluid, biotransformation will take place once the drugs or TCMs are absorbed by the body, leading to the changes of their pharmacological activity. Some active components are metabolized into low active, even inactive produets, while some components of no obvious pharmacological effect *in vitro* will become active. Biological samples are extremely complicated, but CMC makes it convenient to study the components of TCMs and their metabolites in them.

We took rat urine samples after gavage administration of the roots of *Aconitum carmichaeli* Debx. (Fuzi, in Chinese) as an example to make use of CMC. Fuzi is one of the most useful herbal medicines, which has been widely used as an important ingredient in TCMs for their anti-inflammatory, analgesic and cardiotonic effects [@bib0080],[@bib0085]. C~19~ -diterpenoid aconite alkaloids in Fuzi traditionally can be divided into four major types according to the substitute at the C~8~ or C~14~ position: diester-diterpenoid alkaloids (DDAs), monoester-diterpenoid alkaloids (MDAs), alkylolaminediterpenoid alkaloids (ADAs) and other C~19~-diterpenoid alkaloids [@bib0090], [@bib0095], [@bib0100]. Acetyl functions at the C~8~ position in the parent alkaloids, DDAs, are easily hydrolyzed to produce MDAs, and then, the benzoyl or anisoyl functions at the C~14~ position is hydrolyzed to produce the final degradation products, ADAs ([Figure 1](#fig0005){ref-type="fig"}). The detailed mechanism of the metabolism of these alkaloids has scarcely been reported. In rats, aconitine might be metabolized by CYP3A and CYP1A1/2 isoforms in liver microsome, and O-demethylationand N-deethylation were the main metabolic pathways[@bib0105].Figure 1Skeleton of C~19~-diterpenoid aconite alkaloids in Fuzi.

It is not yet clear whether these alkaloids and metabolites exhibit high or low toxicity, or they have additional biochemical activities. It cannot be excluded that some minor compounds may also exert pharmacological effects and therefore play a crucial role in clinical application [@bib0110]. DDAs, mainly, aconitine, hypaconitine and mesaconitine, are well known active and toxic ingredients, while MDAs show a much lower toxicity than that of DDAs. However, the pharmacological studies showed that MDAs and ADAs have significant active actions that would be the desired effects [@bib0115],[@bib0120]. So these structural analogs, alkaloids sharing the common skeleton, may have similar pharmacological effects. CMC can be used for identification of active compounds from biological samples which contain both herbs and metabolites.

In this paper, we have successfully established an offline two-dimensional (2D) System, which combined a rat cardi-ac muscle/CMC-time-of-flight mass spectrometry (TOF/MS) with a high Performance liquid chromatography time-of-flight mass spectrometry (HPLC-TOF/MS). This System was applied to investigate the parent drugs and metabolites in rat urine samples after administration of Fuzi extract. According to the total ions chromatogram (TIC) of CMC-TOF/MS System, components of urine retained by CMC were collected into 30 fractions. Then these samples were analyzed by HPLC-TOF/MS System. On the basis of semi-quantification of these samples, retention behaviors of each compound on CMC were simulated. Finally, relationship between the structure of compounds and affinity reflected by CMC was evaluated. To our knowledge, it is the first time that CMC was applied to *in vivo* studies.

2. Experimental {#sec0010}
===============

2.1. Chemicals and materials {#sec0015}
----------------------------

The herbal medicine Fuzi was purchased from Dekang Drug Store (Shanghai, China) and authenticated by the Department of Pharmacognosy, School of Pharmacy, Second Military Medical University (Shanghai, China). HPLC-grade acetonitrile was purchased from Merck (Darmstadt, Ger-many) and formic acid was obtained from Fluka (Buchs, Switzerland). Pure water was purchased from Hangzhou Wahaha Group Co., Ltd. (Shanghai, China). Macro-porous silica gel (5 *μ*m*,* 120 Å) and empty column (2.1 mm × 30 mm) were obtained from the Welch Materials Inc. (Shanghai, China). All other reagents and solvents were of analytical grade.

2.2. Preparation of Fuzi samples {#sec0020}
--------------------------------

Extracting solution of Fuzi was prepared using refluent water extraction method. 50 g of sample was placed into a 1000 mL round bottomed flask. 500 mL pure water (10 times their total weight) was added and then decocted to boil keeping for 2 h. The extracted solution was filtered through four layers gauze. To the filtrate, 1000 mL ethanol was added, at a filtrate/ethanol ratio of 1:2 (v/v) to pre-cipitate the polysaccharide and protein. This sample was kept overnight at 4°C and then filtered through two layers filter paper, and the filtrate was evaporated to dryness under reduced pressure with a rotary evaporator at 60°C. The residue was dissolved in water to obtain an oral solution of Fuzi with a concentration of 5 g/mL (crude drugs). From the above oral solution, 0.2 mL was diluted and made up to 25 mL by addition of water. The diluted sample solution (FZ) was filtered through a 0.22 *μ*m membrane before use. An aliquot of 5 *μ*l of each sample was injected into the HPLC System.

2.3. Collection of urine samples {#sec0025}
--------------------------------

Four male Sprague-Dawley rats (200--250 g body weight) were provided by the Experimental Animal Center, Second Military Medical University (Shanghai, China). The animals were fasted for 12 h with free access to water before the experiments. Then they were housed in separate metabolic cages with free access to water. Blank urine (U0~A~, U0~B~, U0~c~ and U0~D~) of each rat was collected during a 12 h collection period, after which the rats were given regulär food and water for a week. Then the rats were fasted for 12 h with free access to water, and administered Fuzi extract orally at a single dose of 50 g/kg. Post dose urine (U1~A~, U1~B~, [U1]{.smallcaps}~[c]{.smallcaps}~ and U1~D~) was collected from each rat by the 12 h urine collection procedure. The experiment was conducted in accordance with the National Institute of Health guidelines regarding the principles of animal care (2004).

2.4. Pretreatment of urine samples {#sec0030}
----------------------------------

All urine samples were centrifuged at 10800 rpm for 10 min and the supernatant obtained was stored at --20°C until additional extraction and analysis. 100 *μ*l of each blank urine sample was mixed into a 400 *μ*l mixture of blank urine (U0~M~), and the same Steps were conducted to make mixed dosed urine (U1~M~). A volume of 800 *μ*l of methanol was added to the urine sample (U0~M~ and U1~M~, separately), and the mixture was vortex-mixed for 2 min and then centrifuged at 10800 rpm for 10 min. Then the supernatant was evaporated to dryness under a stream of N~2~ gas. The residue was redissolved in 80 *μ*l pure water, and an aliquot of 5 *μ*l was injected directly into the CMC system. From the above concentrated urine sample, 10 *μ*l was diluted and made up to 500 *μ*L by addition of pure water. An aliquot of 5 *μ*l of diluted sample was injected into the HPLC system.

2.5 Rat cardiac muscle/CMC module {#sec0035}
---------------------------------

Male Sprague-Dawley rats (200--250 g body weight) were from the Experimental Animal Center, Second Military Medical University (Shanghai, China). The rat cardiac muscle cell membrane was prepared as described [@bib0065], [@bib0125], [@bib0130]. After cervical dislocation, the heart of rat was harves-ted immediately and the heart atrium was removed. The cardiac muscular tissue was immerged into pre-cooled normal saline to wash out the bloodiness. After cutting into pieces in 10 mL pre-cooled normal saline, the tissue was put into a glass homogenizer for homogenizing. The homogenate was then centrifuged at 3000 × g for 10 min. 10 mL Tris-HCl (pH 7.4, 50 mM) was added to the pellet to produce a cell suspension, which was ruptured by sonication for 30 min immediately. The resulting suspension was vortex-mixed and clarified by centrifugation at 1000 × g for 10 min. The pellet was discarded, and the suspension was recovered by centrifugation at 12000 × g for 20 min. The pellet was resuspended in 10 mL phosphate buffer saline (pH 7.4, 50 mM) and cell membranes were collected by centrifugation at 12000 × g for 20 min. The pellet was resuspended in 5 mL distilled water. All the above operations were conducted under conditions at 4°C.

Cell membrane stationary phase (CMSP) was prepared according to literature [@bib0005], [@bib0010]. Briefly, 0. 15 g silica was activated at 120°C for 30 min and used as a carrier. It was then homogenized with the cell membrane suspension, i.e., the mixture was slowly added to it under a vacuum and with agitation at 4°C. The mixture obtained was packed into the column using a wet method to yield a CMSP column (2.1 mm × 30 mm, 5 *μ*m). This CMC module was validated by negative and positive controls. They were solutions of salvianolic acid B (SAB), furosemide (FR), dobutamine (DB) and phentolamine (PT), with concentration of 0.5 mg/mL, which were prepared separately by dissol-ving in normal saline. The life-span of this CMC column was about 5 days under a continuous usage.

2.6 CMC-TOF/MS system {#sec0040}
---------------------

The analysis of urine sample on cell membrane chromatography system was performed on an Agilent 1100 series HPLC system (Agilent Corp., Germany) consisting of a quaternary solvent delivery system, a thermostatically controlled column apartment and a diode array detector. Chromatographic separation was carried out on a rat cardiac muscle/CMC column (2.1 mm × 30 mm, 5 um) at 37°C. The mobile phase was 10 mM ammonium acetate solution at a flow rate of 0.2 mL/min. Then it totally flowed into the mass spectrometer source. The DAD wavelength was 230 nm for urine sample, 330 nm for FR and 280 nm for others.

Detection was performed by an Agilent orthogonal TOF/MS (Agilent Corp., USA) equipped with an ESI interface. The TOF/MS analysis was performed using full scan mode and mass range was set at *m/z* 100--1000 in positive ion mode. The conditions of ESI source were as follows: drying gas (N~2~) flow rate, 9 L/min; drying gas temperature, 350°C ; Nebulizer, 35 psig; capillary voltage, 4000 V; fragmentor voltage, 180 V; skimmer voltage, 60 V; octopole RF, 250 V. Tuning mix (G1969-85000, Agilent Corp., USA) was used for lock mass calibration in the assay.

Eluate of the dosed urine (U1~M~) on CMC system within 30 min was collected as one fraction per minute. In all, 30 fractions were collected and labeled as R~1~--R~30~.

2.7 HPLC-TOF/MS System {#sec0045}
----------------------

The analysis of samples (FZ, U0~M~, U1~M~, R~1~-R~30~) was performed on an Agilent 1290 series HPLC system (Agilent Corp., USA) consisting of a binary solvent delivery system and a thermostatically controlled column apartment. Chromatographic separation was carried out on an Agilent ZOR-BAX SB-C18 column (4.6 mm × 150 mm, 5 *μ*m) at 25°C. The mobile phase consisted of 0.1% aqueous formic acid (v/v) (A) and acetonitrile (B), using a gradient elution of 5%--25% B at 0--25 min, 25%--45% B at 25--35 min, 45%--45% B at 35--40 min. Afterwards, the column was rinsed for 5 min with 95% B, the B content lowered to 5% over 2 min, and the column was re-equilibrated for 10 min. The flow rate was kept at 0.8 mL/min, and a post column split was used to maintain a flow rate of 0.3 mL/min into the mass spectrometer source to obtain good nebulization efficiency.

Detection was performed by an Agilent 6538 UHD Accurate-Mass Q-TOF/MS (Agilent Corp., USA) equipped with an ESI interface. The TOF/MS analysis was performed using full scan mode and mass range was set at *m/z* 100--1000 in positive ion mode. The conditions of ESI source were as follows: drying gas (N~2~) flow rate, 11 L/min; drying gas temperature, 350°C ; Nebulizer, 45 psig; capillary voltage, 4000 V; fragmentor voltage, dynamic adjustment from 120 to 385 V; skimmer voltage, 45 V; octopole RF, 250 V. All the data were processed byAgilent MassHunter Software Ver. B. 02. 00. Tuning mix (G1969-85000, Agilent Corp., USA) was used for lock mass calibration in our assay.

Parent components and metabolites were identified according to the analysis of FZ, U0~M~ and U1~M~. Then each compound was extracted from R~1~--R~30~ using the extract ion chromatography (EIC) mode.

3. Results and discussion {#sec0050}
=========================

3.1. Validation of CMC module {#sec0055}
-----------------------------

Salvianolic acid B (antioxidants) and furosemide (diuretic) were used as negative controls and dobutamine (βl adrenoceptor agonists) and phentolamine (α adrenoreceptor blocker) were used as positive controls to validate the specification of this CMC module. Their retention behavior was compared and the results are shown in [Figure 2](#fig0010){ref-type="fig"}. SAB and FR could not be retained on rat cardiac muscle/CMC module. However, DB and PT could be retained obviously, and their retention time was 5.77 min and 10.17 min, respectively. It indicated that this CMC module could selectively retain the components that act on α adrenoreceptor or β adrenoceptor. This CMC module could be used for screen-ing such components from TCM preliminarily.Figure 2Chromatograms of the negative controls and positive controls on the rat cardiac muscle/CMC module. **A**, SAB; **B**, FR; **C**, DB; **D**, PT.

3.2. Collection of fractions {#sec0060}
----------------------------

At present, various two-dimensional systems have been established, which combined CMC as the first dimension and HPLC-MS or GC-MS as the second dimension [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]. On the basis of the analysis of the first dimension, retention components were collected into many fractions. Then offline or online analysis of the second dimension was carried out. UV detectors are often used as the detection methods of the CMC Systems. However, they may not be suitable for the biological samples for the concentrations of components are too low or some compounds are of weak UV absorption. It is difficult to deteet the DDAs *in vivo* by UV detector because of the low level of concentration and rapid biodegradation [@bib0115], and the degradation products show weaker UV absorbance than the parent alkaloids. However, specific detection by TOF/MS techniques could provide determination of these alkaloids.

We used both UV and TOF/MS to determine the urine samples with the purpose of collecting all the retained components. The ultraviolet spectrum and the total ions chro-matogram (TIC) of the dosed urine (U1~M~) are shown in [Figure 3A and 3B](#fig0015){ref-type="fig"} respectively. Compared with the ultraviolet spectrum, the TIC indicated more information due to the high sensitivity of the TOF/MS detector. There were many compounds retained by the CMC within 30 min whichwere demonstrated in the TIC, while it was almost a straight line in the ultraviolet spectrum after 5 min. If we only collected and analyzed the components within 5 min, we might lose much information, because the binding affinity shows a positive correlation with the retention time according to the principle of cell membrane chromatography. With the purpose of comprehensive two-dimensional chromatography, the more fractions collected within 30 min, the more information would be obtained. Fractions were collected each minute, totally 30 fractions. Taking into account the dead volume of the System and the time delayed of the eluent from detection to collection, collection was delayed for 0.5 min, i.e. fraction 0.5 min to 1.5 min was collected and labeled as R~1~, fraction 1. 5 min to 2. 5 min was collected and labeled as R~2~, and so on.Figure 3The ultraviolet spectrum and the TIC of the dosed urine (U1~M~) on the cell membrane chromatography system. **A**, HPLC-DAD spectrum of U1~M~ monitored at 230 nm; **B**, HPLC-TOF/MS TIC of U1~M~

3.3. Identification of components {#sec0065}
---------------------------------

The typical base peak chromatograms (BPCs) of the Fuzi extract (FZ), the dosed urine (U1~M~) and the blank urine (U0~M~) are shown in [Figure 4A, 4B and 4C](#fig0020){ref-type="fig"} respectively. According to our previous work [@bib0135], 24 parent components and 10 potential metabolites were identified. The identification results are shown in [Table 1](#tbl0005){ref-type="table"}. This provides a foundation for further identification of active compounds from biological samples.Figure 4The typical base peak chromatograms (BPCs) of the Fuzi extract (FZ), the dosed urine (U1~M~) and the blank urine (U0~M~). **A**, BPC of FZ; **B**, BPC of U1~M~; **C**, BPC of U0~M~.Table 1Identification of the parent compounds and the potential metabolites from the dosed rat urineIDRT (min)\[M+H\]+ *m/z*FormulaIdentificationCl4.862394.2593C~22~H~35~NO~5~KarakolidineC25.495394.2593C~22~H~35~NO~5~ChuanfumineC38.093424.2699C~23~H~37~NO~6~SenbusineC48.442486.2703C~24~H~39~NO~9~MesaconineC58.861364.2488C~21~H~33~NO~4~16-β×-hydroxycardiopetalineC69.228424.2699C~23~H~37~NO~6~SenbusineC79.861408.2750C~23~H~37~NO~5~IsotalatizidineC810.898358.2382C~22~H~31~NO~3~SongorineC912.787454.2805C~24~H~39~NO~7~FuzilineCIO13.846438.2856C~24~H~39~NO~6~NeolineCll16.443422.2906C~24~H~39~NO~5~TalatizamineC1218.976452.2648C~24~H~37~NO~7~ChasmanineC1321.104464.3012C~26~H~41~NO~6~14-acety ltalatizamineC1421.683606.2908C~31~H~43~NO~11~14-benzoyl-10-OH-mesaconineC1526.562590.2965C~31~H~43~NO~10~BenzoylmesaconineC1628.909604.3122C~32~H~45~NO~10~BenzoylaconitineC1730.077574.3016C~31~H~43~NO~9~BenzoylhypaconitineC1831.376558.3067C~31~H~43~NO~8~14-benzoyl-3,13-deoxyaconineC1931.594646.3227C~34~H~47~NO~11~AconitineC2031.856588.3173C~32~H~45~NO~9~BenzoyldeoxyaconitineC2132.991542.3118C~31~H~43~NO~7~14-benzoylneolineC2235.131616.3122C~33~H~43~NO~10~HypaconitineC2335.633600.3173C~33~H~45~NO~9~13-deoxyhypaconitineC2437.172630.3278C~34~H~47~NO~10~DeoxyaconitineMl6.237424.2699C~23~H~37~NO~6~Demethylated metabolite of neolineM26.816394.2593C~22~H~35~NO~5~Demethylated metabolite of isotalatizidineM38.541394.2593C~22~H~35~NO~5~Demethylated metabolite of isotalatizidineM48.999336.2175C~l9~H~29~NO~4~UnknownM512.470424.2699C~23~H~37~NO~5~Isomer of demethylated metabolite of neolineM613.267408.2750C~23~H~37~NO~5~Demethylated metabolite of talatizamineM715.821450.2856C~25~H~39~NO~6~Demethylated metabolite of 14-acetyltalatizamineM828.418574.3016C~31~H~43~NQ~9~Demethylated metabolite of benzoyldeoxyaconitineM932.195588.2809C~31~H~41~NO~10~UnknownMIO35.142618.2914C~32~H~43~NO~11~Demethylated metabolite of mesaconitine

3.4. Simulation of elution curves {#sec0070}
---------------------------------

A total of 1020 (34 × 30) extracted ion chromatograms (EICs) were obtained by extracting 34 compounds from 30 collected fractions (R1--R30). According to the Q-TOF semi-quantitative analysis of the fractions, the peak areas of target compounds in EICs were recorded. Then 34 scatter plots, with normalized peak area on the vertical axis and serial number of collected fraction on the horizontal axis, were finished. Actually, the serial number of fraction represents the retention time of fraction on CMC column, i.e., the retention time of corresponding constituent, so the scatter graph of a compound is the simulated elution curve of it on the CMC system.

Take the component C16 (Benzoylaconitine, \[M+H\]^+^ *m/z* 604.3122) as an example. EICs were obtained by extracting *m/z* 604.3122 (± 5 ppm) from 30 collected fractions. Consequently, the compound C16 can be detected in the collected fractions R~8~-R~15~, and had the maximum peak area in fraction Rio ([Figure 5A](#fig0025){ref-type="fig"}). It cannot be detected in fractions R~1~-R~7~ and R~16~-R~30~, so the peak areas of C16 were regarded as 0 in them. Then the simulated elution curve of C16 on the CMC System was obtained by plotting the normalized peak area versus serial number of collected fraction ([Figure 5B](#fig0025){ref-type="fig"}). [Table 2](#tbl0010){ref-type="table"} gives a concise and intuitional descrip-tion of retention behavior of the 34 compounds on the CMC System. Peaks on CMC column were broadened from Start time to End time, and most of them were tailing peaks.Figure 5Process of simulating the scatter plot of C16 (Benzoylaconitine) on the CMC system. **A**, EICs of **U**~8~-**U**~15~ by extracting *m/z* 604.3122 (± 5 ppm); **B**, simulated elution curve of C16.Table 2Retention behavior of the 34 compounds on the CMC systemIDStart (min)RT~CMC~^a^End (min)IDStart (min)RT~CMC~[a](#tblfn0005){ref-type="table-fn"}End (min)C14530C18212325C2101227C19141521C36720C20171821C44511C21242530C5131730C22192227C691015C23232426C7111423C24222530C8252530Ml3514C97825M26725C1091124M391013C11222430M46718C12222325M57815C13222430M6171930C14458M7141623C156716M8101214C1681015M9111314C17141626M10202125[^1]

3.5. Evaluation of structure activity relationship {#sec0075}
--------------------------------------------------

According to the principle of cell membrane chromatography, longer retention time indicates stronger binding affinity. As shown in [Table 2](#tbl0010){ref-type="table"}, different components had different retention time. For instance, the components C8, C21 and C24 had the maximum retention time of about 25 min, while the Cl, C4, C14 and mL had the minimum retention time of about 5 min. These differences may attribute to the diversity of their structures. So the relationship between the structure of compounds and binding affinity reflected by CMC---in other words, pharmacology activity---was evaluated.

### 3.5.1. Effect of deacylation and debenzoylation {#sec0080}

When the DDAs became MDAs, i.e. acetyl functions at the C~8~ position were hydrolyzed, the retention time on CMC System reduced. For example, compound C19 (Aconitine) is a DDA, and retention time of C19 on CMC is about 15 min ([Figure 6A](#fig0030){ref-type="fig"}). Its hydrolysis product C16 (Benzoylaconitine) is a MDA, which had the retention time of 10 min ([Figure 6B](#fig0030){ref-type="fig"}). That means the affinity decreased with the deacylation. It is the same with C22 (Hypaconitine, RT~CMC~ = 22 min) and C17 (Benzoylhyp-aconitine, [RT]{.smallcaps}~CMC~ ^=^ 16 min) ([Figure 6C and 6D](#fig0030){ref-type="fig"}). In a similar way, when the benzoyl functions at the C~14~ position of MDAs were hydrolyzed to produce the ADAs, the binding affinity weakened. For example, when C15 (Benzoylmesaco-nine) break down to form C4 (Mesaconine), the retention time on CMC System reduced from 7 to 5 min ([Figure 6E and 6F](#fig0030){ref-type="fig"}). As suggested above, the affinity decreased with the deacylation and debenzoylation, which could partly explain the fact that MDAs show lower toxicity than that of DDAs.Figure 6Simulated elution curves of certain compounds on the CMC system. **A**, CI9 (Aconitine); **B**, CI6 (Benzoylaconitine); **C**, C22 (Hypaconitine); **D**, CI7 (Benzoylhypaconitine); **E**, CI5 (Benzoylmesaconine); **F**, C4 (Mesaconine); **G**, C7 (Isotalatizidine); **H**, **M**2; I, **M**3; **J**, CIO (Neoline); **K**, M1; **L**, **M**5.

### 3.5.2. Effect of demethylation {#sec0085}

Simulated elution curves of C7 (Isotalatizidine), M2 and M3 are shown in [Figure 6G, 6H and 6I](#fig0030){ref-type="fig"} respectively. M2 and M3 were considered to be the probable metabolites of C7 because the methyl functions at the C~16~ or C~18~ position of the parent compounds might degrade to form the metabolites. The retention time of *C7* was 14 min, which was longer than that of M2 (7 min) and M3 (10 min). Similarly, mL and M5 were considered to be the potential metabolites of C10 (Neoline), and their retention time was 5 min, 8 min and 11 min, respectively ([Figure 6K, 6L and 6J](#fig0030){ref-type="fig"}). M6 was supposed to be the potential metabolite of Cll (Talati-zamine) and their retention time was 19 min and 24 min, respectively. All the retention time of the parent compounds was longer than that of the corresponding demethylation products. To sum up, the affinity decreased as the process of demethylation. All the above results are listed in [Table 3](#tbl0015){ref-type="table"}.Table 3Relationship between structures and retention time of certain compoundsGroupIDRT~CMC~ (min)[a](#tblfn0010){ref-type="table-fn"}Differences in structure[b](#tblfn0015){ref-type="table-fn"}1C1915C~8~ = 0-acetylC1610C~8~ = OH2C2222C~8~ = 0-acetylC1716C~8~ = OH3C157C~14~ = 0-benzoylC45C~14~ = OH4C714C~16~ = O-methylC~18~ = O-methylM27C~16~ = OHC~18~ = O-methylM310C~16~ = O-methylC~18~ = OH5C1011C~16~ = O-methylC~18~ = O-methylM15C~16~ = OHC~18~ = O-methylM58C~16~ = O-methylC~18~ =  = OH6C1124C~16~ = O-methylM619C~16~ = OH[^2][^3]

4. Conclusion {#sec0090}
=============

The establishment of an offline two-dimensional System, which combined a rat cardiac muscle/CMC-TOF/MS with an HPLC-TOF/MS, is characterized by high sensitivity and convenience, and can be used in the case of investigating the parent compounds and metabolites in urine samples. By using the semi-quantification and curve fitting method, binding affinities of different compounds on cell mem-branes were compared and influences of some functional groups on activity were estimated. It showed that some minor components, such as C8 (Songorine), C21 (14-benzoylneoline) and C24 (Deoxyaconitine), exerted stronger affinities than the known aconitine and hypaconitine. Further research is needed to see whether these compounds can exhibit activity or toxicity and, therefore, play a key role in Fuzi. This work also demonstrates, for the first time, that the cell membrane chromatography can be applied to *in vivo* study.
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[^1]: Retention time was supposed to be the number of fraction which had the maximum peak area.

[^2]: Retention time was estimated based on the simulated elution curves.

[^3]: The same parts of structure are not listed in each group.
